{"id":62878,"date":"2026-04-01T16:02:31","date_gmt":"2026-04-01T14:02:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/"},"modified":"2026-04-01T16:02:31","modified_gmt":"2026-04-01T14:02:31","slug":"vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/","title":{"rendered":"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System"},"content":{"rendered":"
\n

MAPLE GROVE, Minn.–(BUSINESS WIRE)–VDYNE, Inc. (\u201cVDYNE\u201d or \u201cthe Company\u201d), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company\u2019s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe IDE approval enables initiation of a U.S. pivotal study at leading clinical centers to evaluate the safety and effectiveness of the VDYNE system in patients with severe tricuspid regurgitation (TR).<\/p>\n

\n\u201cThis is a defining milestone for VDYNE and an important step toward bringing a much-needed therapy to patients with severe tricuspid regurgitation,\u201d said Mike Buck, Chief Executive Officer. \u201cOur focus now is on disciplined clinical execution and partnering with leading investigators to generate high-quality data that advances the field and improves patient care.\u201d<\/p>\n

\nSignificant unmet clinical needs exist in the treatment of TR with 1.5 million people in the US suffering from TR with a small percentage of those patients eligible to receive surgical treatment.2<\/sup> Severe TR is linked to poor prognosis and high mortality (10% at one year), yet current treatment options remain extremely limited3<\/sup>.<\/p>\n

\nVDYNE\u2019s TTVR system is designed as a patient-tailored, minimally invasive solution to address the complexities of tricuspid valve anatomy and disease. Since first-in-human use in November 2023, the system has been used globally through clinical studies and compassionate use, providing important insights into procedural performance and clinical outcomes.<\/p>\n

\nAbout VDYNE, Inc.<\/b><\/p>\n

\nVDYNE, Inc. is a privately held medical device company focused on developing innovative transcatheter valve replacement technologies for the treatment of tricuspid regurgitation. Headquartered in Maple Grove, Minnesota, VDYNE is dedicated to transforming care for patients suffering from right heart valve disease.<\/p>\n

\nThe VDYNE Tricuspid Valve Replacement System is currently under clinical investigation and not commercially available in the United States or any other country.<\/p>\n

\nAbout Tricuspid Regurgitation<\/b><\/p>\n

\nTricuspid regurgitation (TR) occurs when the tricuspid valve fails to close properly, allowing blood to flow backward into the right atrium. This condition can lead to fatigue, fluid retention, and reduced quality of life and is associated with significant mortality and morbidity.<\/p>\n

\n[1] TRIVITA Trial: VDyne Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients with Symptomatic Severe Tricuspid Valve Regurgitation
\n
[2] Demir OM, Regazzoli D, Mangieri A, Ancona MB, Mitomo S, Weisz G, Colombo A, Latib A. Transcatheter Tricuspid Valve Replacement: Principles and Design. Front Cardiovasc Med. 2018 Sep 19;5:129. doi: 10.3389\/fcvm.2018.00129. PMID: 30283790; PMCID: PMC6156134.
\n
[3] Kolte D, Elmariah S. Current state of transcatheter tricuspid valve repair. Cardiovasc Diagn Ther. 2020 Feb;10(1):89-97. doi: 10.21037\/cdt.2019.09.11. PMID: 32175231; PMCID: PMC7044094.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations
\n
VDYNE, Inc.
\n
investor@vdyne.com<\/a>
www.vdyne.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MAPLE GROVE, Minn.–(BUSINESS WIRE)–VDYNE, Inc. (\u201cVDYNE\u201d or \u201cthe Company\u201d), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company\u2019s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62878","6":"format-standard","7":"category-industry"},"yoast_head":"\nVDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MAPLE GROVE, Minn.–(BUSINESS WIRE)–VDYNE, Inc. (\u201cVDYNE\u201d or \u201cthe Company\u201d), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company\u2019s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-01T14:02:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260401672745\/en\/2763279\/22\/VDYNE-LOGO-JPEG-cover.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System\",\"datePublished\":\"2026-04-01T14:02:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/\"},\"wordCount\":458,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260401672745\\\/en\\\/2763279\\\/22\\\/VDYNE-LOGO-JPEG-cover.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/\",\"name\":\"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260401672745\\\/en\\\/2763279\\\/22\\\/VDYNE-LOGO-JPEG-cover.jpg\",\"datePublished\":\"2026-04-01T14:02:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260401672745\\\/en\\\/2763279\\\/22\\\/VDYNE-LOGO-JPEG-cover.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260401672745\\\/en\\\/2763279\\\/22\\\/VDYNE-LOGO-JPEG-cover.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/","og_locale":"en_US","og_type":"article","og_title":"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System - Pharma Trend","og_description":"MAPLE GROVE, Minn.–(BUSINESS WIRE)–VDYNE, Inc. (\u201cVDYNE\u201d or \u201cthe Company\u201d), a privately held medical device company developing next generation transcatheter valve replacement technologies, today announced that the U.S. Food & Drug Administration (FDA) has approved an investigational device exemption (IDE) for the company\u2019s pivotal clinical trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system. The IDE ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/","og_site_name":"Pharma Trend","article_published_time":"2026-04-01T14:02:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260401672745\/en\/2763279\/22\/VDYNE-LOGO-JPEG-cover.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System","datePublished":"2026-04-01T14:02:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/"},"wordCount":458,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260401672745\/en\/2763279\/22\/VDYNE-LOGO-JPEG-cover.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/","url":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/","name":"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260401672745\/en\/2763279\/22\/VDYNE-LOGO-JPEG-cover.jpg","datePublished":"2026-04-01T14:02:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260401672745\/en\/2763279\/22\/VDYNE-LOGO-JPEG-cover.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260401672745\/en\/2763279\/22\/VDYNE-LOGO-JPEG-cover.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/vdyne-receives-fda-approval-to-initiate-the-trivita1-ide-pivotal-trial-of-transcatheter-tricuspid-valve-replacement-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"VDYNE Receives FDA Approval to Initiate the TRIVITA1 IDE Pivotal Trial of Transcatheter Tricuspid Valve Replacement System"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62878"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62878\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}